Skip to content
value.today
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc.

GANX
$74 Mmarket cap on Oct 7, 2026+26.0% since Jan 2024
Compare
World rank
#19,829
Revenue
—
For year ending December-2025
Net income
$-20 M
SEC filing
Employees
20
As of December 31, 2025
SEC filing

Gain Therapeutics, Inc. in brief

Gain Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Bethesda, Maryland, USA. It was founded in 2017. Its market value was $74 M on 7 October 2026, which makes it the 19,829th largest listed company in the world and the 3,679th largest in the USA on this site. It employs about 20 people and Gene Mack is its chief executive. Its shares trade under the symbol GANX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Gain Therapeutics, Inc.

We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.

GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people with Parkinson’s disease with or without a GBA1 mutation.

We have generated an extensive preclinical data package providing evidence of the mechanism of action and safety of GT-02287. In preclinical models of GBA1 and idiopathic Parkinson’s disease, GT-02287 has been shown to restore glucocerebrosidase, or GCase, function in the lysosome, improve mitochondrial health, reduce toxic lipid substrates and toxic forms of alpha-synuclein, reduce neuroinflammation, improve survival of dopaminergic neurons, increase dopamine levels, completely restore locomotor function and improve cognition, and reduce plasma-based neurodegeneration maker, neurofilament light chain (NfL) back to the level of healthy animals.

From the company's annual report filed with the US SEC: read the report

Gain Therapeutics, Inc. timeline

3 events, 2017–2021
  1. 2017
  2. 🏁
    · approximate
    Founded
  3. 2020
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 22 March 2021; shares registered for exchange trading on 17 March 2021.

Events of Gain Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$41 M$82 M$123 M$164 M2023202420252026

World rank over time

▲ up 5,597 places since 2022
2022-01-07: #25518#25,51820222022-12-25: #26655#26,65520222023-07-30: #25475#25,47520232024-01-05: #24159#24,15920242026-03-08: #9376#9,37620262026-08-01: #17593#17,59320262026-10-07: #19921#19,9212026

Rank in USA: #4,763 (Jan 2022) · #4,975 (Dec 2022) · #4,763 (Jul 2023) · #3,982 (Jan 2024) · #1,810 (Mar 2026) · #3,460 (Aug 2026) · #3,657 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
4.0×
Free cash flow yield
-25.4%
Net margin
—
Operating margin
—
Return on equity
-108.6%
Liabilities / assets
18.6%
Net debt
$-20M
Revenue growth
-57.1%
R&D / revenue
19200.0%
Profit per employee
$-1.0 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-4M—FY20Fiscal year ending Dec 2021: revenue $0M, net income $-14M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-18M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-22M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-20M—FY24Fiscal year ending Dec 2025: revenue —, net income $-20M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-19M$-20M—
Dec 2024——$-20M$-20M—
Dec 2023$0M-57.1%$-22M$-22M-37116.7%
Dec 2022$0M-12.5%$-18M$-18M-12564.3%
Dec 2021$0M—$-14M$-14M-8681.3%
Dec 2020——$-3M$-4M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-18M——$-0.61—
Dec 2024$-19M$0M$-19M$-0.89—
Dec 2023$-19M$0M$-19M$-1.71—
Dec 2022$-15M$0M$-15M$-1.48—
Dec 2021$-12M$0M$-12M$-1.37—
Dec 2020$-3M$0M$-3M$-1.33—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025: revenue —, net income $-6M—Jun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-6M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-3M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Gain Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-19 M
Net income
$-20 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$23 M
Total liabilities
$4 M
Total equity
$19 M

As of December-2025

Top 50 institutional investors in Gain Therapeutics, Inc.#

As of Sep 30, 2026
50 institutions held 8.4 M shares (about 19.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 14.8%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Gain Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Marshall Wace, LLP1,680,811-242,735 (-12.62%)3.77%$3 MNov 13, 2026
2Potomac Capital Management, Inc.930,000-16,400 (-1.73%)2.09%$2 MNov 13, 2026
3Jones Financial Companies Lllp739,432+130,840 (+21.50%)1.66%$1 MNov 13, 2026
4Gsa Capital Partners LLP634,716+2,585 (+0.41%)1.43%$1 MNov 16, 2026
5Cambridge Investment Research Advisors, Inc.566,645-570,645 (-50.18%)1.27%$1 MNov 2, 2026
6DME Capital Management, LP566,1300 (0.00%)1.27%$1 MNov 16, 2026
7Vanguard Capital Management LLC480,2690 (0.00%)1.08%$1 MNov 13, 2026
8Geode Capital Management, LLC469,535+16,034 (+3.54%)1.05%$1 MNov 6, 2026
9BlackRock, Inc.268,321-6,636 (-2.41%)0.60%$0 MNov 13, 2026
10UBS Group AG241,483+26,471 (+12.31%)0.54%$0 MNov 10, 2026
11Vanguard Fiduciary Trust Co231,5340 (0.00%)0.52%$0 MNov 13, 2026
12Cresset Asset Management, LLC220,000+60,000 (+37.50%)0.49%$0 MNov 16, 2026
13State Street Corp199,537+42,000 (+26.66%)0.45%$0 MNov 12, 2026
14Renaissance Technologies LLC182,600New0.41%$0 MNov 12, 2026
15Citadel Advisors LLC170,230+15,706 (+10.16%)0.38%$0 MNov 16, 2026
16LPL Financial LLC117,2510 (0.00%)0.26%$0 MNov 6, 2026
17Morgan Stanley105,772-20,200 (-16.04%)0.24%$0 MNov 13, 2026
18Northern Trust Corp97,0130 (0.00%)0.22%$0 MNov 16, 2026
19Commonwealth Equity Services, LLC57,881-575 (-0.98%)0.13%$0 MNov 2, 2026
20Bridgeway Capital Management, LLC52,238+22,234 (+74.10%)0.12%$0 MNov 16, 2026
21Empowered Funds, LLC52,238New0.12%$0 MNov 13, 2026
22Prelude Capital Management, LLC35,8200 (0.00%)0.08%$0 MNov 16, 2026
23Apollon Wealth Management, LLC31,500+5,000 (+18.87%)0.07%$0 MOct 23, 2026
24Simplex Trading, LLC28,457New0.06%$0 MNov 4, 2026
25StoneX Group Inc.25,118New0.06%$0 MNov 3, 2026
Show all 50: investors 26 to 50
Institutional investors 26 to 50 in Gain Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Oliver Luxxe Assets LLC20,2500 (0.00%)0.05%$0 MOct 14, 2026
27Bokf, NA20,000New0.04%$0 MOct 27, 2026
28Vanguard Global Advisers, LLC18,3760 (0.00%)0.04%$0 MNov 13, 2026
29HighTower Advisors, LLC17,1740 (0.00%)0.04%$0 MNov 10, 2026
30Wealth Enhancement Advisory Services, LLC17,0560 (0.00%)0.04%$0 MOct 13, 2026
31Wealthspire Advisors, LLC16,9000 (0.00%)0.04%$0 MNov 13, 2026
32Jpmorgan Chase & Co15,960+14,260 (+838.82%)0.04%$0 MNov 12, 2026
33Sandhill Capital Partners LLC15,4000 (0.00%)0.03%$0 MNov 12, 2026
34Crux Wealth Advisors14,925New0.03%$0 MNov 10, 2026
35HRT Financial LP14,903New0.03%$0 MNov 13, 2026
36Benedict Financial Advisors Inc13,500-21,500 (-61.43%)0.03%$0 MOct 7, 2026
37HB Wealth Management, LLC12,7830 (0.00%)0.03%$0 MOct 23, 2026
38R Squared Ltd11,584New0.03%$0 MNov 6, 2026
39Harbour Investments, Inc.10,7450 (0.00%)0.02%$0 MNov 9, 2026
40NewEdge Advisors, LLC10,6000 (0.00%)0.02%$0 MNov 13, 2026
41Mercer Global Advisors Inc /adv10,0000 (0.00%)0.02%$0 MNov 16, 2026
42Sanctuary Advisors, LLC10,0000 (0.00%)0.02%$0 MNov 13, 2026
43Tower Research Capital LLC (TRC)4,728-3,593 (-43.18%)0.01%$0 MNov 16, 2026
44Royal Bank Of Canada2,278New0.01%$0 MNov 16, 2026
45Arax Advisory Partners1,7000 (0.00%)0.00%$0 MNov 12, 2026
46Wells Fargo & Company/mn1,000-8,400 (-89.36%)0.00%$0 MNov 16, 2026
47Pinnacle Financial Group, Inc.600—0.00%$0 MNov 16, 2026
48Caitong International Asset Management Co., Ltd101-64 (-38.79%)0.00%$0 MOct 29, 2026
49Larson Financial Group LLC100 (0.00%)0.00%$0 MNov 5, 2026
50Barclays PLC2-1,350 (-99.85%)0.00%$0 MNov 6, 2026

Mutual funds holding Gain Therapeutics, Inc.#

9 funds hold shares worth $2 M (about 2.2% of the company). Since their previous reports 7 added shares and 1 sold, buying $0 M net.
Mutual funds holding Gain Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.430,902$1 M0.97%<0.01%+7.8%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC207,106$0 M0.47%<0.01%+6.7%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors144,159$0 M0.32%0.02%+51%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC57,335$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC55,636$0 M0.12%<0.01%+6.5%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC30,004$0 M0.07%0.04%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC28,629$0 M0.06%<0.01%+185%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,730$0 M0.02%<0.01%+49%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC966$0 M<0.01%<0.01%+32%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Gain Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
6
since
$116 K-$5 K$0Dec 2023: bought $0 (0 trades), sold $5 K (2 trades)Dec 23Mar 2024: bought $116 K (1 trades), sold $0 (0 trades)MarJul 2024: bought $21 K (2 trades), sold $0 (0 trades)JulAug 2024: bought $65 K (2 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Gain Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Khalid IslamExecutive Chairman, DirectorBuy+50,000$1.000$50 K50,000Form 4
filed Gene MackCFO and Interim CEOBuy+14,400$1.010$15 K14,400Form 4
filed Eric I. RichmanDirectorBuy+5,000$1.230$6 K277,629Form 4
filed Eric I. RichmanDirectorBuy+12,000$1.210$15 K289,629Form 4
filed Jeffrey Scott RileyDirectorBuy+30,000$3.860$116 K30,000Form 4
filed Matthias AlderChief Executive Officer, DirectorOption exercise+18,750——25,763Form 4
filed Matthias AlderChief Executive Officer, DirectorOption exercise+825——26,588Form 4
filed Matthias AlderChief Executive Officer, DirectorOption exercise+637——27,225Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Gain Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.9 M
9.2% of shares · 5.55 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-1 split ; 10-for-1 split

Trading halts

  • 2025-12-18 15:03 UTC, code LUDP, resumed 15:13 UTC
  • 2025-12-18 14:56 UTC, code LUDP, resumed 15:01 UTC
  • 2025-12-18 14:41 UTC, code LUDP, resumed 14:56 UTC
  • 2025-12-18 14:30 UTC, code LUDP, resumed 14:40 UTC

Fails to deliver

  • : 5,043 shares at $1.67
  • : 4,565 shares at $1.75
  • : 399 shares at $2.01
  • : 1,424 shares at $2.12
  • : 4,211 shares at $2.17

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Gain Therapeutics, Inc. scorecard#

Passes 3 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 7, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.0×Price to book 4.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-25.4%Free cash flow is -25.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.61 vs -0.89Diluted EPS -0.61 in fiscal 2025 against -0.89 the year before (report's currency).
    • ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$4 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-155.7%-155.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 4
    • ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.64 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.02 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $20 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year44.1%Diluted shares up 44.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Gain Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Gain Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue——0.10.10.20.0
Research and development1011128.47.22.3
General and administrative8.59.6119.56.81.2
Operating expenses19202218143.5
Operating income−19−20−22−18−14−3.5
Interest expense and finance costs————0—
Net interest income——0.50.40.00.0
Income before tax−19−20−22−17−14−3.6
Income tax0.90.50.10.10.00.0
Net income including minority interests−20−20−22−18−14−3.6
Net income attributable to shareholders−20−20−22−18−14−3.6
Earnings per share, basic-0.61-0.89-1.71-1.48-1.37-1.33
Earnings per share, diluted-0.61-0.89-1.71-1.48-1.37-1.33
Shares, weighted average (basic)33231312102.7
Shares, weighted average (diluted)33231312102.7
Balance sheet
Cash and cash equivalents2110127.3377.5
Short-term investments——5.013——
Receivables—————0.0
Other current assets1.20.90.70.80.70.2r
Current assets22121821389.0
Property, plant and equipment0.10.10.10.10.10.0
Right-of-use (leased) assets0.30.20.50.70.90.5
Other intangible assets0.1—————
Non-current assets0.60.50.83.01.30.6
Total assets23121924399.6
Accounts payable0.80.91.31.60.61.0
Debt due within a year0.10.10.10.10.10.0
Current liabilities3.43.94.94.12.62.1
Long-term debt0.30.30.40.50.60.7
Lease liabilities (non-current)0.20.10.20.40.70.4
Non-current liabilities0.90.91.11.11.61.3
Total liabilities4.34.86.05.24.23.4
Retained earnings−101r−61−39−21−7.0−3.5
Shareholders' equity197.31319356.2
Total liabilities and equity23121924399.6
Shares outstanding42271612123.5r
Cash-flow statement
Depreciation and amortization0.10.10.10.10.00.0
Share-based compensation1.82.43.31.50.80.1
Cash from operating activities−18−19−19−15−12−3.2
Capital expenditure—−0.0−0.0−0.1−0.1−0.0
Cash from investing activities—5.010−15−0.1−0.0
Debt issued—————0.7
Cash from financing activities281313−0.14210
Exchange-rate effect on cash0.5−0.50.5−0.00.1−0.0
Change in cash10−1.44.5−30297.2
Report10-Q10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Gain Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 4 · Material agreement 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

Gain Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Gain Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$10 MNo. 1$10 to $50 million48equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Gain Therapeutics, Inc. compares in Biotechnology

  • Market cap$74 M · higher than 32% of 726
  • Revenue growth-57.1% · higher than 16% of 438
  • Price / book4.0× · lower than 38% of 534
  • FCF yield-25.4% · higher than 38% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Gain Therapeutics, Inc.🇺🇸$74 M——-57.1%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 7, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Gain Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Gain Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Gain Therapeutics, Inc.? Suggest a correction